IXICO plc Release: Appointment Of Chief Financial Officer

17 September 2014, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, announces that Susan Lowther FCMA has been appointed to the board as Chief Financial Officer with effect from 1 October 2014. Susan (aged 54) was previously Group Chief Financial Officer and a director of Novacyt SA, a European company listed on the French Alternext exchange. Novacyt specialises in cancer and infectious disease diagnostic products and services, operating from four sites in France and the UK.

Prior to this she was Chief Financial Officer and a director of Lab21 Group Limited, which was acquired by Novacyt in June 2014 by way of a share for share transaction valuing the enlarged group at c.€40 million. Susan was previously Chief Executive Officer at BioWisdom Limited and has held finance roles in life science companies including RiboTargets, Lonza Biologics, Celltech Group and Monsanto.

Commenting on the appointment Derek Hill, CEO of IXICO, said: "We are delighted that Susan is joining the IXICO team. She brings a depth of financial and business experience that will help us continue to grow the business internationally." Information in respect of Susan required pursuant to Schedule 2(g) of the AIM Rules for Companies is set out below.

Full name:
Susan Day Lowther
Current directorships:
TriSys Business Software Limited
Novacyt S.A.
Lab21 Limited
Lab21 Healthcare Limited
Lab21 Inc
Microgen Limited
Mercia Diagnostics Limited
Biotec Laboratories Limited
Selah Technologies Limited
Previous directorships:
BioWisdom Limited
BioWisdom SRS Limited

OmniViz Inc

NPTech Services Limited (Wholly owned subsidiary of Lab21 Limited which was dissolved in July 2014 as part of a group reorganisation)
Myconostica Limited (Wholly owned subsidiary of Lab21 Limited which was dissolved in August 2014 as part of a group reorganisation)
Myconostica Trustee Company Limited (Wholly owned subsidiary of Myconostica Limited which was dissolved in April 2014 as part of a group reorganisation)
Lab21 Diagnostic Services Limited (subsidiary of Lab21 Limited which was dissolved in April 2014 as part of a group reorganisation)

Enquiries:

IXICO plc
Derek Hill, CEO
Charles Spicer, VP Corporate Development
+44 20 3763 7499

Peel Hunt LLP (Nominated Adviser and Broker)
James Steel
Clare Terlouw
+44 20 7418 8900

Daniel Stewart & Company (Joint Broker)
Mark Treharne
David Hart
+44 207 776 6550

FTI Consulting Limited (Investor Relations)
Simon Conway
John Dineen
+44 20 3727 1000

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.